

World Medical Innovation Forum

The World Medical Innovation Forum is a global gathering of more than 1,000 senior health care leaders in the heart of Boston. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives.

The 2017 World Medical Innovation Forum will feature the newest technologies to diagnose, treat and manage cardiovascular and cardiometabolic disease.

CARDIOVASCULAR | May 1–3, 2017 worldmedicalinnovation.org

Cardiovascular Care

Cardiovascular and cardiometabolic care are among the core drivers of the current healthcare revolution. With 24 million heart disease-related deaths forecasted for 2030, current legacy delivery systems are undergoing disruption by a convergence of new therapies, new technologies, digital integration and the engagement of completely new industries to move patients to improved health and sustained well-being.

At more than \$200 billion annually, cardiovascular remains health care's largest market. It is dominated by drugs for the treatment of hypertension, hyperlipidemia, thrombosis, and cardiomyopathy, as well as devices for coronary and peripheral vascular interventions, rhythm management, and valve repair. See first hand how these traditional fields are being transformed by innovative approaches combining new therapies, 'omics, digital diagnostics, education and engagement with new delivery platforms to significantly enhance the lives of millions of patients worldwide.

Every Speaker An Expert. Every Panel Unique. Every Seat Invaluable.

Featured speakers include more than 100 CEOs, Senior Harvard Medical School faculty, top cardiovascular innovators, leading investors and national journalists.



Robert Bradway
CEO, Amgen



Michael Mahoney CEO, Boston Scientific



George Barrett CEO, Cardinal Health



Omar Ishrak, PhD CEO, Medtronic



John Lechleiter, PhD Chairman, Eli Lilly and Company



John Flannery CEO, GE Healthcare



Frans van Houten CEO, Philips



Michael Mussallem CEO, Edwards Lifesciences



Timothy Ring CEO, Bard



Tony Coles, MDCEO, Yumanity Therapeutics



Jessica Mega, MD CMO, Verily



Nancy Brown CEO, American Heart Association



Gary Gibbons, MD
Director, NHLBI



Sue Siegel CEO, GE Ventures & healthymagination



Bernd Montag, PhD CEO, Siemens Healthcare



Jonathan Rennert CEO, ZOLL Medical



Michael Minogue CEO, Abiomed



Stéphane Bancel CEO, Moderna



Robert Califf, MD Commissioner (former), Food and Drug Administration



Tamara Syrek JensenDirector, Coverage and
Analysis Group, CMS



Betsy Nabel, MD President, Brigham and Women's Hospital



Paul Fonteyne CEO, Boehringer Ingelheim USA



Richard Migliori, MD EVP Medical Affairs and CMO, UnitedHealth Group



Paul LaViolette
Managing Partner and COO
SV Life Sciences Advisers



Michael Jaff, DO
President, Newton-Wellesley
Hospital, Partners HealthCare,
Professor of Medicine,
Harvard Medical School



Ora Pescovitz, MD
SVP and US Medical Leader,
Eli Lilly and Company



Jean-François Formela, MD Partner, Atlas Venture



Joseph Loscalzo, MD, PhD

Chairman, Department of Medicine, Physician-in-Chie Brigham and Women's Hospital; Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School



Katrina Armstrong, MD

Physician-in-Chief,
Department of Medicine,
Massachusetts General
Hospital; Jackson Professor
of Clinical Medicine,
Harvard Medical School



Jeff Mirviss SVP and President, Peripheral Interventions, Boston Scientific



Tassos Gianakakos CEO, MyoKardia



Fouzia Laghrissi-Thode, MD VP, Therapy Area, Cardiovascular & Metabolism,

Panels

ATHEROSCLEROSIS

- 1. New Targets in Coronary Artery Disease
- 2. CLINICAL HIGHLIGHT: A New Chapter of PAD

CLINICAL EVIDENCE & CARE PATHWAY

- 3. **CLINICAL HIGHLIGHT:** Optimizing Care for the 51%: New Market Opportunities
- 4. Global Clinical Trials: Next Generation Design and Scalability
- 5. Reinventing Cardiac Care
- 6. Innovation in Translational Trials

HEART FAILURE

7. Heart Failure's Therapeutic Mandate

INNOVATION AND POLICY

- CEO Roundtable: Today's Learnings, Tomorrow's Opportunities
- 9. Pricing to Enable Affordability and Innovation
- 10. 1:1 Fireside Chat: Robert Califf, MD, Commissioner (former), Food and Drug Administration
- 11. CV Investing in the Next Decade

METABOLIC SYNDROME

- 12. **FOCUS SESSION:** Japan Today: Advancing Cardiometabolic Therapies
- 13. The Skinny on Fat: Therapeutic Opportunities

MODALITIES

- 14. Disruptive Therapeutic Platforms: New Tools, New Outcomes
- 15. Personal Monitoring for Disease Management
- 16. Precision Cardiovascular Medicine: What is Different This Time

RHYTHM DISORDERS

17. Tackling the AFib Epidemic

STRUCTURAL HEART

18. **CLINICAL HIGHLIGHT:** Emerging Devices for Complex Structural Heart Disease

SPECIAL HIGHLIGHTS

Austen-Braunwald Innovation Award

Directors Perspective:

Current and Former NHLBI Heads

Discovery Cafés*

Disruptive Dozen

First Look*

Details on page 5

18 total, under development



Breakthrough Technologies



First LookThe Next Wave of Cardiovascular Breakthroughs
Monday | May 1, 2017 | 8AM

Young Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Twenty rising stars from Brigham and Women's Hospital and Massachusetts General Hospital will present in 10-minute sessions.

Austen-Braunwald Innovation Award Honoring Two Pioneers

The inaugural Austen-Braunwald Innovation Award will be awarded to honor a single BWH and single MGH First Look presenter who embodies the innovative, entrepreneurial and forward thinking of these global leaders. The two \$10,000 awards will be granted based on selection committee on overall presentation quality, innovativeness, commercial potential, caliber of disruption and market need.



W. Gerald Austen, MD Surgeon-in-Chief, Emeritus, MGH; Chairman, MGH Chiefs Council; Edward D. Churchill Distinguished Professor of Surgery at HMS



Eugene Braunwald, MD
Physician-in-Chief, Emeritus, BWH;
Founding Chair, TIMI Study Group;
Distinguished Hersey Professor of
Medicine at HMS



Discovery Cafés

Lunch with Top Cardiovascular Leadership from across Partners HealthCare

Monday | May 1, 2017 | NOON

Intensive 90-minute workshops led by senior Harvard faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

included.
Cardiac Replacement Therapy: The Next Ten Years
Heart Failure: Back in The Game through New Pathways
Payment Models: Provider's Perspective

Molecular Imaging:

New Biological Endpoints – Function Over Structure

Open Innovation in Medical Devices: What is it? What Are the Barriers?

Wearables for Cardiovascular Health: How to Validate and Integrate in Care Paths? Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?



Disruptive Dozen

Celebrate the Selection of the 12 Most Disruptive Technologies in Cardiovascular Care

Wednesday | May 3, 2017 | NOON

Harvard faculty from Brigham and Women's Hospital and Massachusetts General Hospital select the technologies that will have the greatest impact on cardiovascular and cardiometabolic care in the next decade. The top 12 will be announced by a panel of BWH and MGH clinical experts.

Steering Committee



Calum MacRae, MD, PhD Chief of Cardiovascular Medicine, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School



Anthony Rosenzweig, MD Chief, Cardiology Division, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School



Morris Birnbaum, MD, PhD Disease Research Unit, Pfizer



Elazer Edelman, MD, PhD Women's Hospital; Professor of Medicine, Harvard Medical School; Thomas D. and Sciences and Technology, MIT



Jean-François Formela, MD



Michael Jaff, DO Harvard Medical School




Farouc Jaffer, MD, PhD



Division, Massachusetts General Hospital; Associate Professor of Medicine,



Sekar Kathiresan, MD





Anne Klibanski, MD

Laurie Carrol Guthart Professor of Medicine, Harvard Medical School



Paul LaViolette Managing Partner and COO,



Laura Mauri, MD

Center for Clinical Biometrics and Harvard



Robert Plenge, MD, PhD

Vice President, Merck



Marc Sabatine, MD

Medicine, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School



Christine Seidman, MD

Director, Cardiovascular Genetics Center, of Medicine, Harvard Medical School



Jagmeet Singh, MD, DPhil

Associate Chief, Cardiology Division, Center: Professor of Medicine.



Thor Sundt, MD

Chief, Division of Cardiac Surgery, Professor of Surgery, Harvard Medical School



Craig Thompson, MD



Malissa Wood, MD

Associate Professor of Medicine, Harvard Medical School

Sponsors

STAKEHOLDER



Advancing science for life™

STRATEGIC









COLLABORATOR













STAT

World Medical Innovation Forum Audience



Clinicians and Investigators	34%
Life Science and Biopharmacuetical	28%
Device and HIT	11%
Venture and Legal	11%
Foundations and Government	9%
Media	5%
Other	2%



95%

of 2016 attendees felt the World Forum exceeded expectation

Connect with Us

Partners HealthCare Innovation

@PartnersWMIF

YOUTUBE

World Medical Innovation Forum

world medical innovation.org

worldmedicalinnovation.org/blog



The World Medical Innovation Forum is brought to you by:













